Merck & Eisai's cancer drug combo shows progress in some but not all key trials for gastroesophageal cancer.

Merck & Co. and Eisai's Phase 3 study of Keytruda and Lenvima in gastroesophageal cancer showed a statistically significant improvement in progression-free survival but did not meet the primary endpoint of overall survival. The combination treatment's safety profile was consistent with previous studies. The drugs are approved for several cancers and are under study for others.

2 months ago
16 Articles